Last reviewed · How we verify
NCT06844708
CMTS0929 for Inflammatory Bowel Disease
EARLY_PHASE1 trial testing CMTS0929 in Inflammatory Bowel Disease (IBD) in 12 participants. Not yet recruiting.
31 January 2030
Quick facts
| Lead sponsor | The Second Hospital of Nanjing Medical University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 20 February 2025 |
| Primary completion | 31 January 2030 |
| Estimated completion | 1 July 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- CMTS0929 — full drug profile →
Conditions studied
- Inflammatory Bowel Disease (IBD) — all drugs for Inflammatory Bowel Disease (IBD) →
Sponsor
The Second Hospital of Nanjing Medical University
Who can join
Adults 18 to 75, any sex, with Inflammatory Bowel Disease (IBD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, open-label, single-arm study to explore the safety and the efficacy of China Microbiota Transplantation System 0929 (CMTS0929) for patients with inflammatory bowel disease (IBD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06844708
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CMTS0929
Trials testing the same drug.
- NCT06836427 — CMTS0929 for Clostridioides Difficile Infection · EARLY_PHASE1 · not yet recruiting
Other recruiting trials for Inflammatory Bowel Disease (IBD)
Currently open trials in the same condition.
- NCT07245394 — Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) · recruiting
- NCT07237516 — Zymfentra (Infliximab-dyyb) REal World Cohort STudy · recruiting
- NCT07224113 — Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD · recruiting
- NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting
- NCT07355101 — Personalized Exercise Coaching to Improve Quality of Life in Pediatric IBD · NA · active not recruiting
Other The Second Hospital of Nanjing Medical University trials
Trials by the same sponsor.
- NCT07331688 — CMTS0515-auWMT for Radiation Enteritis · Phase 1, PHASE2 · active not recruiting
- NCT06839586 — CMTS4520 for Chronic Diarrhoea in Adults · Phase 1, PHASE2 · active not recruiting
- NCT06836427 — CMTS0929 for Clostridioides Difficile Infection · EARLY_PHASE1 · not yet recruiting
- NCT06839599 — CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults · Phase 1, PHASE2 · not yet recruiting
- NCT06832176 — CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Constipation in Adults · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06844708 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Second Hospital of Nanjing Medical University
- Last refreshed: 25 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06844708.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing